️Macro Alpha Analytics
Ir al canal en Telegram
欢迎加入 【Macro Alpha Analytics】 ⚖️ 法律声明 : 📌 分享性质: 本群所有观点纯属个人意见分享,不构成买卖建议 (No Buy/Sell Recommendation)。 📌 专业咨询: 在做出任何投资决定前,请务必咨询专业持牌理财顾问或您的股票经纪。 📌 责任豁免: 阁下须对自身的财务决策负全责。本群不对任何投资亏损、交易风险或决策后果承担任何法律责任。 ⚠️ 风险提示: 市场波动无常,投资需根据自身财务承受能力审慎操作。
Mostrar más6 444
Suscriptores
Sin datos24 horas
-307 días
-14730 días
Archivo de publicaciones
*Yenher Holdings* (RM0.85) - *Grains to gains*
Tan Kai Sheun initiates coverage on Yenher with a BUY rating with TP of RM1.42 based on 16x mid-FY26 PER.
*Animal nutrition health specialist*
Yenher is principally involved in the manufacturing and distribution of animal health and nutrition products. In 1H24, manufacturing made up 55.5% of gross profit, while distribution accounted for the remaining 44.5%.
Under manufacturing, around two-third of gross profit contribution comes from premix, 22% from complete feed, and the remaining from biotech feed additives and farm equipment.
*Multi-fold capacity expansion in new plant*
Yenher is undertaking an expansion in its manufacturing with the construction of a new plant in Batu Kawan, which is expected to become operational in stages from 2H25.
This new facility will significantly increase the premix production capacity by around 4.5x.
It will also introduce a new division for complete animal feed production, covering aquaculture, pet, swine, and poultry.
This expansion addresses its current capacity constraint, adds a new revenue stream and aims to meet the strong domestic and international demand for its competitive products.
*Expansion of biotech feed additive segment through JV*
Yenher recently entered into a JV with Denmark-based Fermentationexperts A/S (FE) to form YH European Protein Asia Sdn Bhd (YHEPA), which will manufacture, market, and sell plant proteins and fermented palm kernel meal. Yenher holds a 60% stake in YHEPA.
Initially, YHEPA will source products from FE and begin marketing and selling in 4Q24. Subsequently in-house production should commence by late 2025.
This JV expedites the growth in the group’s biotech feed additives segment and may have potential tax incentives.
*Beneficiary of Ringgit recovery*
The recent strengthening of the Ringgit vs USD should benefit Yenher, given that a significant portion of its manufacturing costs are USD-denominated.
Kai's sensitivity analysis shows that if the USD-MYR rate improves from 4.66 to a range of 4.30-3.80, Yenher’s profit could increase by 13.7-32.6%, while its GP margin could potentially expand from the current 25% to above 30%.
The strengthened Ringgit should also lead to lower capex for its imported machineries.
*Capex and revenue potential*
Yenher's expansion for its new factory and the initial phases under JV requires a capex of RM86m.
*Yenher’s current net cash of RM73m or 24.3 sen per share* (alongside future cash generation) should be able to sufficiently fund the capex, while it also has further debt headroom of RM120m for future investments.
Upon full utilization, the new factory and JV are projected to increase manufacturing revenue by approximately 5x vs FY23.
With an estimated 80% utilization by FY30, Kai estimates that PATAMI could potentially grow to RM63.5m, implying a strong 6-year CAGR of 20.5%.
*Forecasts*
Kai forecasts FY24-26 core earnings to grow at a CAGR of 18.5% with estimated FY24/25f/26f earnings of RM20.8/24.1/29.2m.
Core net EPS (sen):
FY23 a : 7.0
FY24 e : 6.9
FY25 f : 8.0
FY26 f : 9.7
*Kai initiates coverage with a BUY rating and a TP of RM1.42* based on a P/E of 16x mid-FY26 PER.
Kai reckons the premium valuation vs. peers is justified by Yenher's market leadership, major capacity expansion, and a stronger Ringgit which warrants a sector re-rating.
Kai highlights that Yenher is now entering an exciting multi-year growth phase that could potentially see the group’s earnings doubling or even tripling in the coming years.
07 oct 2024, 20:13
Edit, Sign and Share PDF files on the go. Download the Acrobat Reader app: https://adobeacrobat.app.link/Mhhs4GmNsxb
07 oct 2024, 20:12
中国股市将在今日恢复交易 ‼️
全球资本持续涌入中国股市,并看好中国股市的未来趋势。华尔街投行:花期 、高盛、摩根士丹利和瑞银纷纷上调 A 股的目标 🔼
07 oct 2024, 19:56
China’s Brokers Skip Holidays to Staff Up for ‘Hectic’ Reopening https://www.bloomberg.com/news/articles/2024-10-07/china-s-brokers-skip-holidays-to-staff-up-for-hectic-reopening
07 oct 2024, 19:49
Scholar Rock shares jump 300% after rare disease drug scores trial win | Reuters
https://www.reuters.com/business/healthcare-pharmaceuticals/scholar-rocks-genetic-disease-drug-meets-main-goal-late-stage-trial-2024-10-07/
07 oct 2024, 11:31
单单中芯国际一家公司的交易额就超过 100 亿港元 🤯 马股千家多公司今日加起来的成交额才 20 亿左右 🙈
07 oct 2024, 10:22
07 oct 2024, 05:08
https://www.freemalaysiatoday.com/category/business/2024/10/07/foreign-investors-dispose-rm1-1bil-worth-in-net-equities/
Regionally, MIDF reported an exodus of foreign funds from Asia last week as foreign investors net sold in six out of the eight markets that it tracked.
The net foreign fund outflow was at a 24-week high at US$7.31b on the back of a rotation of funds into China. Only the Philippines and Vietnam saw net inflows last week, it added.
07 oct 2024, 00:24
近期最头疼的应该是那些把私下配售全部扫的不法分子,现在应该怎么办?手里满仓的票 💣
基金被套,散户几乎被割完了 🙈
06 oct 2024, 23:34
就像 Harry 大哥上周五所说,马股缺乏的是“信心”,投资者们的信心大损害,就连一些基金大佬都避而远之马股了。
现在的马股看开盘 15 分钟就行了,过后就可以忙其它东西了
06 oct 2024, 21:34
